Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus carboplatin/taxane induction followed by pembrolizumab with or without MK-2870 maintenance in metastatic squamous NSCLC
2023-510128-66-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised trial in Pulmonary squamous cell carcinoma comparing Pembrolizumab + MK-2870 maintenance with Pembrolizumab maintenance (2 arms). Primary endpoint: Overall survival. Planned start Aug 2024; status: authorised.
02
Drugs
pembrolizumabsacituzumab tirumotecan
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2023-510128-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510128-66-00.